Trials / Recruiting
RecruitingNCT05687747
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- National University Hospital, Singapore · Academic / Other
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI | 68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts. |
Timeline
- Start date
- 2023-08-18
- Primary completion
- 2025-08-01
- Completion
- 2026-02-01
- First posted
- 2023-01-18
- Last updated
- 2025-04-04
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05687747. Inclusion in this directory is not an endorsement.